Skip to content

Handersson Barros

8 papers in the library · 90 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression

Journal of Psychopharmacology July 8, 2026 Raynara Bolcont, Fernanda Palhano-Fontes, Handersson Barros et al.

BACKGROUND: -dimethyltryptamine (DMT); however, long-term effects, including broader well-being dimensions, are sparsely explored across populations. AIMS: Investigating whether DMT produces sustained improvements in anxiety, life satisfaction, and quality of life, in both healthy individuals and patients with treatment-resistant depression (TRD). METHODS: In 2 open-label clinical trials, 27...

DOI: 10.1177/02698811261465005 (opens in new tab) Anxiety Life satisfaction Depression economics Optimism +8

DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality

Research Square May 20, 2026 Isabel Wießner, Marcelo Falchi-Carvalho, Sophie Laborde et al. preprint

Abstract Paradoxically, psychedelics have long been used as models of both psychosis and therapy. After proposing mystical experiences as a link between these models for lysergic acid diethylamide (LSD), we aimed to extend and refine this framework for N,N -Dimethyltryptamine (DMT). In a randomised, placebo-controlled, double-blind, crossover study, 25 healthy participants received DMT (60mg)...

Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial.

European Neuropsychopharmacology June 17, 2025 Isabel Wießner, Marcelo Falchi-Carvalho, Sophie Laborde et al. 7 citations

Vaporized N,N-Dimethyltryptamine (DMT) has a short duration and simple application, prompting this technique as a new approach for psychedelics' clinical use. Building on our initial dose-ascending studies and addressing potential confounding effects of dosing order, this study is the first to evaluate inhaled DMT in a randomized, placebo-controlled, double-blind design. Given DMT's therapeutic...

DOI: 10.1016/j.euroneuro.2025.06.002 (opens in new tab) Full text (opens in new tab) Psychedelic therapy N,N-Dimethyltryptamine Placebo-controlled study Psychedelics +17

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.

Neuropsychopharmacology May 1, 2025 Marcelo Falchi-Carvalho, Fernanda Palhano-Fontes, Isabel Wießner et al. 35 citations

Depression affects over 185 million people worldwide, with approximately one-third classified as treatment-resistant depression (TRD). Current treatments, such as oral antidepressants, often take around 3 weeks to become effective, with no immediate anti-suicidal benefits. The field urgently needs innovative therapies that provide rapid relief. Psychedelics like psilocybin and ayahuasca have...

DOI: 10.1038/s41386-025-02091-6 (opens in new tab) Full text (opens in new tab) Mental health Depression treatment Psychedelic medicine Clinical research +1

The Antidepressant Effects of Vaporized N,N-Dimethyltryptamine: An Open-Label Pilot Trial in Treatment-Resistant Depression.

Psychedelic Medicine March 1, 2025 Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al. 16 citations

N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew, has shown antidepressant effects. This open-label clinical trial investigates for the first time the efficacy of vaporized DMT in treatment-resistant depression (TRD). Six TRD patients participated in an open-label, fixed-order, dose-escalation study, receiving a lower (15 mg)...

Expressive resource in a clinical psychedelic study: Art as an integration tool.

Progress in Brain Research 2025 Handersson Barros, Marcelo Falchi-Carvalho, Lucas O. Maia et al. 2 citations

Psychedelic experiences, especially those induced by substances such as N,N-Dimethyltryptamine (DMT), are often characterized by high subjective intensity, complex visual content, and notable ineffability-that is, the difficulty of being fully expressed in words. This expressive limitation poses a significant challenge to the integration of the experience, which is essential for the therapeutic...

DOI: 10.1016/bs.pbr.2025.07.004 (opens in new tab) Full text (opens in new tab) Clinical trials Expressive resource Mandala N,N-Dimethyltryptamine DMT +2

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.

European Neuropsychopharmacology March 1, 2024 Marcelo Falchi-Carvalho, Isabel Wießner, Sérgio Ruschi B Silva et al. 25 citations

Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) last over several hours, inhaled N,N-Dimethyltryptamine (DMT) effects last around 10 min, which might provide a cost- and time-effective alternative to the clinical application of oral psychedelics. We aimed at...

DOI: 10.1016/j.euroneuro.2023.12.006 (opens in new tab) Full text (opens in new tab) Entheogens Clinical trial Dose-response study Mood disorders +6

The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression

medRxiv January 4, 2024 Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al. 5 citations preprint

Abstract Introduction N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew has shown antidepressant effects. This Phase 2a clinical trial investigates for the first time the efficacy of isolated DMT in treatment-resistant depression (TRD). Methods Six TRD patients participated in an open-label, fixed-order, dose-escalation study,...